Ecolab Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; the filing also presents unaudited quarterly data. Ecolab provides water, hygiene, infection-prevention and related services globally. On June 3, 2020, it separated its Upstream Energy business, ChampionX, in a Reverse Morris Trust transaction; ChampionX is reported as discontinued operations, and prior periods were recast for continuing operations.
Financial performance
| Metric | FY2020 | FY2019 | Change / context |
|---|---|---|---|
| Net sales | $11.79 billion | $12.56 billion | Down 6% reported; down 5% at fixed currency and 7% acquisition-adjusted fixed currency. Volume fell 9%, partly offset by 2% pricing. |
| Gross margin | 41.4% GAAP; 41.8% adjusted | 43.9% GAAP; 44.2% adjusted | Adjusted margin declined 2.4 percentage points, mainly from lower volume, reduced operating leverage and mix. |
| Operating income | $1.40 billion GAAP; $1.62 billion adjusted | $1.85 billion GAAP; $2.00 billion adjusted | Down 24% GAAP and 19% adjusted. |
| Continuing-operations net income attributable to Ecolab | $967 million | $1.43 billion | Down 32%. |
| Diluted EPS | $3.33 continuing operations; $(4.15) total reported | $4.87 continuing operations; $5.33 total reported | Adjusted continuing-operations diluted EPS was $4.02, down 21% from $5.12. |
| Operating cash flow | $1.74 billion continuing operations | $2.05 billion continuing operations | Down $305 million. Total operating cash flow, including discontinued operations, was $1.86 billion. |
| Cash and debt at year-end | $1.26 billion cash; $6.69 billion total debt | $119 million cash; $6.35 billion total debt | Net debt was $5.43 billion; net debt/EBITDA was 2.4x versus 2.3x. |
Ecolab declared $1.89 per share in dividends for 2020, up from $1.85 in 2019. Capital expenditures were $489 million, versus $731 million in 2019. The company reported $18.1 billion in total assets and $11.9 billion in total liabilities at year-end.
Segment trends
- Global Industrial: Fixed-currency sales declined 1%; operating income increased 23%. Industrial water and food-and-beverage performance was mixed, while Downstream sales fell 8% amid reduced transportation-fuel demand.
- Global Institutional & Specialty: Fixed-currency sales fell 19% and operating income fell 66%. Institutional sales declined 27% as restaurant, lodging and travel activity contracted; Specialty sales grew 8%, supported by food retail demand.
- Global Healthcare & Life Sciences: Fixed-currency sales rose 21% and operating income rose 67%, driven by pandemic-related hygiene demand and life-sciences growth.
- Other: Fixed-currency sales declined 10% and operating income declined 21%, reflecting pandemic-related weakness, including in Textile Care and Colloidal Technologies.
Material changes and unusual items
- The reported 2020 net loss attributable to Ecolab was $1.21 billion, including a $2.17 billion after-tax loss from discontinued operations. The ChampionX separation loss was $2.14 billion, including the write-off of cumulative translation adjustments; the loss was primarily a transaction-accounting effect rather than continuing-operations performance.
- Continuing-operations special charges totaled $312 million, including $83 million of debt-refinancing charges, restructuring, disposal and impairment costs, COVID-19-related costs, legal matters and product-recall costs. A $28.6 million impairment of an equity-method investment was attributed to the pandemic’s economic and liquidity effects.
- COVID-19 had divergent effects: higher hygiene demand benefited Healthcare & Life Sciences, while restrictions and lower economic activity hurt Institutional, hospitality-related and other businesses. Management cited lower sales, reduced operating leverage and unfavorable mix, partly offset by pricing, cost savings and lower variable compensation.
- Allowance for doubtful accounts increased to $84 million from $56 million; bad-debt expense rose to 0.5% of sales from 0.2%, reflecting deterioration in collectability, particularly among Institutional customers.
- In 2020 Ecolab acquired CID Lines for approximately $507 million in cash and sold Holchem, recognizing a $12.8 million after-tax loss. Two subsequent European acquisitions had aggregate consideration of approximately $100 million and were described as immaterial.
Liquidity, outlook and risks
Management said reasonably foreseeable cash needs for the next 12 months—including debt service, investment, dividends, potential acquisitions and pension contributions—were expected to be funded by cash on hand, operating cash flow and, if needed, borrowing. Year-end cash was elevated partly as a precaution during the pandemic. Ecolab had no commercial paper outstanding and no borrowings under its $2.0 billion revolving credit facility; it reported compliance with debt covenants. Long-term debt ratings were A- from S&P and Fitch and Baa1 from Moody’s.
Management anticipated 2021 results to be generally comparable to 2019, while noting that the pandemic’s evolving course prevented a reliable estimate of its full effects. It expected industrial conditions to improve and Healthcare and Life Sciences conditions to remain favorable, but anticipated continued near-term pressure in full-service restaurants, hospitality, lodging and entertainment. This is an expectation, not a guaranteed forecast.
- Principal risks include prolonged COVID-19 effects and weak customer markets; foreign-exchange, geopolitical, trade and regulatory exposure; cybersecurity and operational disruption, including ongoing ERP upgrades; raw-material cost or supply shocks; and execution and integration risks.
- The ChampionX separation creates potential indemnification disputes and tax risk: Ecolab relied on outside counsel’s tax opinions but did not obtain an IRS ruling. The filing also identifies litigation, environmental remediation, chemical-release and product-regulatory risks. Management did not believe recorded legal and environmental matters posed a reasonably possible material loss beyond accrued amounts, while cautioning that outcomes remain uncertain.
- Restructuring plans continued. Accelerate 2020 was expected to cost $255 million in total and deliver estimated annual savings of $315 million by 2022. A separate Institutional plan was expected to cost $80 million and generate approximately $50 million in savings by the end of 2024; actual costs and savings may vary.
Most important facts for investors to verify
- How quickly restaurant, hospitality and other Institutional end markets recover, and whether Healthcare & Life Sciences growth persists as pandemic-related demand changes.
- Whether operating margins and cash generation improve from 2020 levels, including the effects of volume, mix, bad debts, pricing and cost-saving programs.
- Debt, refinancing and liquidity trends, including progress toward management’s stated credit-rating objectives and net-debt/EBITDA levels.
- Actual restructuring costs, timing and realized savings; also verify acquisition integration and the completion of CID Lines purchase accounting.
- Developments in ChampionX-related tax and indemnity exposures, legal reserves, the European Healthcare product recall, and environmental contingencies.
- Reconcile reported GAAP results with adjusted non-GAAP measures, and distinguish continuing operations from the discontinued ChampionX results.
PwC issued unqualified opinions on the consolidated financial statements and internal control over financial reporting; management also concluded controls were effective at December 31, 2020. Adjusted measures are non-GAAP and should be considered alongside GAAP results.